about
Amyloidosis in Inflammatory Bowel Disease: A Systematic Review of Epidemiology, Clinical Features, and Treatment.Extracolonic Cancer in Inflammatory Bowel Disease: Data from the GETECCU Eneida Registry.Optimizing the Use of Linaclotide in Patients with Constipation-Predominant Irritable Bowel Syndrome: An Expert Consensus Report.Use of polyethylene glycol in functional constipation and fecal impaction.Information resources used by patients with inflammatory bowel disease: Satisfaction, expectations and information gaps.The changes in resting anal pressure after performing full-thickness rectal advancement flaps.Esophageal abnormalities in morbidly obese adult patients.Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study."Core out" or "curettage" in rectal advancement flap for cryptoglandular anal fistula.Secondary amyloidosis in Crohn's disease: treatment with tumour necrosis factor inhibitor.Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy.Magnetic resonance defecography versus videodefecography in the study of obstructed defecation syndrome: Is videodefecography still the test of choice after 50 years?Adaptation to Spanish language and validation of the fecal incontinence quality of life scale.Physician Perspectives on Unresolved Issues in the Management of Ulcerative Colitis: The UC Horizons Project.Clinical and manometric results of endorectal advancement flaps for complex anal fistula.[Irritable bowel syndrome with constipation and functional constipation in adults: Treatment (Part 2 of 2)].[Irritable bowel syndrome with constipation and functional constipation in adults: Treatment (Part 2 of 2)].Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registryGuía de práctica clínica sobre el síndrome del intestino irritablePrevalence and Factors Related to Hepatitis B and C in Inflammatory Bowel Disease Patients in Spain: A Nationwide, Multicenter StudyDisease severity and treatment requirements in familial inflammatory bowel diseaseAproximación diagnóstica y terapéutica al paciente con gastroparesiaActivity of Crohn's disease assessed by colour Doppler ultrasound analysis of the affected loopsLong-term follow-up (42 months) of chronic anal fissure after healing with botulinum toxinAnal endosonographic evaluation after closed lateral subcutaneous sphincterotomyGastroesophageal reflux in diabetes mellitusOesophageal motility disorders in type 1 diabetes mellitus and their relation to cardiovascular autonomic neuropathyAbsence of cardiovascular autonomic dysfunction and vagal pancreatic impairment in idiopathic achalasia of the oesophagusMorphological and functional evaluation of the pancreatic duct with secretin-stimulated magnetic resonance cholangiopancreatography in alcoholic pancreatitis patientsThe ideal lateral internal sphincterotomy: clinical and endosonographic evaluation following open and closed internal anal sphincterotomy[Analysis of experience in the use of dynamic pelvic magnetic resonance imaging in the assessment of obstructive defaecation syndrome][Impact of endorectal advancement flaps in fecal incontinence][Clinical practice guidelines: Irritable bowel syndrome with constipation and functional constipation in adults: Concept, diagnosis, and healthcare continuity. (Part 1 of 2)][Clinical practice guidelines: Irritable bowel syndrome with constipation and functional constipation in adults: Concept, diagnosis, and healthcare continuity. (Part 1 of 2)]
P50
Q30251633-E36C0B4D-63C6-4A60-AC3E-64BC510F8372Q36378458-8BD7F1B7-3247-47EB-83DC-0B62A4AA2AB8Q37699695-71D914C3-89BD-408D-97D2-FD766CDD5EA9Q39015615-B2B0AD35-668C-40BF-A184-8D5E3EA0F008Q39024715-7BA40561-9001-472A-A498-905996BF81B9Q39147020-40825EED-AA87-4BDB-A3DD-6AF14515479FQ40190357-909DF1C5-B2A7-4E3D-A285-0A4F8240E6BEQ40876904-3EAE4519-DA5B-4924-BBC0-4FED18F58732Q41542791-749C47A3-D04D-4840-B653-B95E4624C787Q42844045-6FAC15CB-F121-4138-B206-8EFC8CC75DC7Q42997987-82C67404-6452-4CDA-AADB-2411CCE05729Q43364302-4823D3AA-74CE-45FA-A04D-E2138C6F7D03Q47220001-7F1F1C29-277D-4C65-8D5D-561DED235950Q50279083-5903D4F4-23A4-4526-A635-44BF40B2C1C2Q51149419-E5EE542A-7449-4664-9B7D-4D7A8236261DQ53478280-BE933D0B-38E9-45DB-BB6F-8554CBFCD932Q53842743-FC51CCAE-EF75-45B6-92DC-FC3D09911A3DQ57051384-0869A1A6-6601-4410-B49B-8B8B711069B0Q57231268-C2DA7FB4-8EF9-4FBE-86C0-08D4A39252C0Q59509574-900FCDCF-707B-4D21-8AE9-75AA441EACDDQ61349527-1E626824-8A64-49B9-9EEE-B8CD97211831Q61349534-BC92EBFF-CFC6-448F-A232-5E2807CB0FDEQ74417676-4909F763-26E2-4D9D-A3C0-8F9892A98B8DQ74428286-DEF0CD6F-CDC5-42DD-8F4A-C73928D5C887Q74566220-1F9EDC25-46BA-4FA5-AEC9-8F041B54CA73Q77318945-F3AB6861-ED09-455C-A05C-9D20988ADF69Q80138062-1203E78F-DE5A-4C91-B4A3-D8260756882CQ80639429-289530D3-3F40-4A59-9C9E-B2AF58039E62Q81250973-2B6094A2-5D09-45BA-8034-9E9EA9DE2657Q81663518-4370FC36-A712-4660-A74B-4FF54485A7AAQ83838869-8C903A2B-1273-42AF-AC69-048EA9962510Q84091914-6DB4D5E5-C584-45E3-B479-25059C2EAEAEQ88681082-102C8D95-0AD4-43A6-AD47-526AB441659DQ89354042-BF43E5B7-8C39-4E82-96B8-B713BFE1E151
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Miguel Minguez
@ast
Miguel Minguez
@en
Miguel Minguez
@es
Miguel Minguez
@nl
Miguel Minguez
@sl
type
label
Miguel Minguez
@ast
Miguel Minguez
@en
Miguel Minguez
@es
Miguel Minguez
@nl
Miguel Minguez
@sl
prefLabel
Miguel Minguez
@ast
Miguel Minguez
@en
Miguel Minguez
@es
Miguel Minguez
@nl
Miguel Minguez
@sl
P106
P1153
7004835670
P21
P31
P496
0000-0003-0148-5938